

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 September 2022 (01.09.2022)



(10) International Publication Number
WO 2022/182915 A1

(51) International Patent Classification:
C12N 5/0783 (2010.01)

(21) International Application Number:
PCT/US2022/017774

(22) International Filing Date:
24 February 2022 (24.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/153,920 25 February 2021 (25.02.2021) US
63/153,905 25 February 2021 (25.02.2021) US
63/165,042 23 March 2021 (23.03.2021) US
63/165,021 23 March 2021 (23.03.2021) US
63/167,608 29 March 2021 (29.03.2021) US
63/167,606 29 March 2021 (29.03.2021) US
63/181,224 28 April 2021 (28.04.2021) US
63/273,141 28 October 2021 (28.10.2021) US

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(71) Applicant: **LYELL IMMUNOPHARMA, INC.**
[US/US]; 201 Haskins Way, South San Francisco, California 94080 (US).

(72) Inventors: **VODNALA, Suman Kumar**; 201 Haskins Way, South San Francisco, California 94080 (US). **PATEL, Yogin**; 201 Haskins Way, South San Francisco, California 94080 (US). **RESTIFO, Nicholas P.**; 201 Haskins Way, South San Francisco, California 94080 (US). **EIL, Robert Langland**; 201 Haskins Way, South San Francisco, California 94080 (US).

(74) Agent: **KIM, Ji Eun** et al.; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: METHODS FOR CULTURING CELLS

(57) Abstract: The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells and/or NK cells) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.

WO 2022/182915 A1